Advanced searches left 3/3

Metastatic Melanoma Survival - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.

Metastatic uveal melanoma is a common cause of poor prognosis malignancy. The prognostic and predictive role of soluble immune checkpoints and inflammatory cytokines/chemokines in 22 metastatic UM patients was investigated in this research. A comparison was made between circulating immune profiles of metastatic cutaneous melanoma, for which immunotherapy is a mainstay of treatment, and UM after anti-PD-1 therapy. IL-8, HVEM, and IDO activity among metastatic UM patients with survival rates of more than six months compared to patients with survival 6 months. During anti-PD-1 therapy, several of these molecules were significantly elevated in UM compared to CM patients. Despite immunotherapy and patients with long-lived patients treated with an anti-PD-1 antibody, the analysis of circulating immune molecules helps to distinguish patients with poor prognosis. The difference in serum concentrations of these proteins during anti-PD-1 therapy between UM and CM shows the differing efficacy of immune checkpoint inhibitors.

Source link: https://europepmc.org/article/MED/35258435


Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma.

Methods of Administration The Canadian Melanoma Research Network obtained national prospective data of patients with newly diagnosed BRAF-mutated metastatic melanoma. Patients who received 2L-Irotherapy or those who received 2L-IO showed a trend toward OS improvement in comparison to the 2L-TT group. Nevertheless, we reported evidence that immunotherapy has long-lasting effect in advanced BRAF-mutant melanoma patients, regardless of treatment type, and that Canadian medical oncologists are choosing the right treatment protocols in a real-world setting, based on patient demographics and tumor characteristics.

Source link: https://europepmc.org/article/MED/35323326


Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

By including routine clinical data available at the time of treatment initiation, we sought to develop multivariable predictive models for response and survival to anti-programmed cell death protein 1 monotherapy or in combination with anticytotoxic T-cell lymphocyte-4. Methods One thousand six hundred forty-four patients with metastatic melanoma were treated with anti-PD-1 IPI at 16 centres from Australia, the United States, and Europe were included. Results The following clinical information was used to forecast ORR in immunotherapy-treated patients: The following clinical characteristics were included in the final model: Eastern Cooperative Oncology Group Performance Status, the presence/absence of liver and lung metastases, serum lactate dehydrogenase, blood neutrophil-lymphocyte ratio, and path of therapy. Conclusions A: A new series of regularly collected baseline medical findings can predict the response and survival of patients with metastatic melanoma treated with immunotherapy and may be valuable tools for clinical decision making.

Source link: https://europepmc.org/article/MED/35143285

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions